Foundations Investment Advisors LLC Purchases New Shares in Merck & Co., Inc. (NYSE:MRK)

Foundations Investment Advisors LLC purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 2,735 shares of the company’s stock, valued at approximately $227,000.

A number of other hedge funds have also recently modified their holdings of MRK. Catalyst Private Wealth LLC acquired a new stake in shares of Merck & Co., Inc. during the third quarter valued at about $25,000. Newfound Research LLC purchased a new position in Merck & Co., Inc. in the third quarter valued at about $26,000. Fiduciary Planning LLC purchased a new position in Merck & Co., Inc. in the third quarter valued at about $32,000. Stuart Chaussee & Associates Inc. increased its holdings in Merck & Co., Inc. by 44.3% during the 3rd quarter. Stuart Chaussee & Associates Inc. now owns 433 shares of the company’s stock worth $36,000 after purchasing an additional 133 shares during the last quarter. Finally, Provident Wealth Management LLC acquired a new position in shares of Merck & Co., Inc. in the 3rd quarter valued at approximately $43,000. Hedge funds and other institutional investors own 66.43% of the company’s stock.

Shares of Merck & Co., Inc. stock opened at $82.34 on Thursday. The stock has a market capitalization of $208.32 billion, a price-to-earnings ratio of 18.22, a PEG ratio of 1.96 and a beta of 0.43. Merck & Co., Inc. has a twelve month low of $65.25 and a twelve month high of $92.06. The company has a current ratio of 1.30, a quick ratio of 1.00 and a debt-to-equity ratio of 0.90. The business’s 50 day simple moving average is $81.41 and its 200-day simple moving average is $81.11.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, October 27th. The company reported $1.74 EPS for the quarter, topping the Zacks’ consensus estimate of $1.44 by $0.30. The firm had revenue of $12.55 billion during the quarter, compared to the consensus estimate of $12.21 billion. Merck & Co., Inc. had a return on equity of 53.83% and a net margin of 24.33%. The firm’s revenue was up 1.2% on a year-over-year basis. During the same period in the prior year, the business earned $1.51 EPS. Sell-side analysts predict that Merck & Co., Inc. will post 5.9 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 8th. Investors of record on Tuesday, December 15th were issued a $0.65 dividend. This represents a $2.60 dividend on an annualized basis and a dividend yield of 3.16%. The ex-dividend date of this dividend was Monday, December 14th. This is a boost from Merck & Co., Inc.’s previous quarterly dividend of $0.61. Merck & Co., Inc.’s dividend payout ratio (DPR) is 50.10%.

A number of brokerages recently issued reports on MRK. Sanford C. Bernstein restated an “outperform” rating and issued a $95.00 price target on shares of Merck & Co., Inc. in a research note on Tuesday, November 10th. Mizuho restated a “buy” rating and issued a $100.00 target price on shares of Merck & Co., Inc. in a research note on Sunday, December 6th. JPMorgan Chase & Co. increased their price target on shares of Merck & Co., Inc. from $98.00 to $105.00 and gave the stock an “overweight” rating in a research report on Friday, October 16th. Berenberg Bank assumed coverage on Merck & Co., Inc. in a report on Tuesday, September 29th. They issued a “hold” rating and a $88.00 price objective for the company. Finally, SVB Leerink upped their price objective on Merck & Co., Inc. from $100.00 to $103.00 and gave the company an “outperform” rating in a research note on Thursday, October 29th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $95.36.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. The company offers therapeutic and preventive agents for cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products.

Read More: What Every Investor Needs to Understand About Secondary Public Offerings

Want to see what other hedge funds are holding MRK? Visit to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with's FREE daily email newsletter.